Translational Advances in Oncogene and Tumor-Suppressor Gene Research.
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing molecular mechanisms and clinical applications without primary empirical data or systematic review methodology.
PubMed 40149342 · doi:10.3390/cancers17061008
What was done
The authors conducted a narrative literature review examining the molecular mechanisms of tumor-suppressor genes and oncogenes, their associated signaling cascades (including p53, Rb, Ras/Raf/ERK/MAPK, PI3K/AKT, and Wnt/β-catenin), epigenetic alterations, tumor heterogeneity, and drug resistance. The review also summarized translational applications involving next-generation sequencing, multiomics, pharmacogenomics, and precision oncology interventions.
What was found
The abstract reports no primary quantitative findings or empirical study results. It notes a broad background statistic that approximately one in five people develop cancer in their lifetime, and restates foundational genetic principles: tumor suppressors generally undergo loss-of-function (two-hit) alterations, whereas oncogenes involve gain-of-function (one-hit) mutations that drive dysregulated cell division and survival.
Why it matters
This paper provides an overview linking foundational cancer genetics to modern translational tools like multiomics and next-generation sequencing. It outlines how characterization of specific driver mutations can inform personalized cancer diagnosis, prevention, and targeted therapeutic strategies.
Limits
This is an unsystematic narrative review with no formal search strategy, study selection criteria, or quantitative synthesis. It presents no new clinical or experimental data, precluding independent evaluation of effect sizes, risk of bias, or direct clinical outcomes.
Cited by
- supports Tumor suppressor genes protect against cancer by triggering cell death when cellular damage occurs.